Overview

Rav Purewal is an associate in the Firm’s Corporate Department. Rav’s practice focuses on corporate transactions and governance matters, with experience advising clients across a range of industries and throughout the life cycle of their businesses.

She has significant experience in:

  • Mergers and acquisitions
  • Venture capital and private equity financings
  • Corporate governance and entity formation
  • Securities law and compliance
  • Real estate transactions

Before joining Glaser Weil, Rav practiced at a large international law firm, where she represented public and private companies in venture capital financings, capital markets transactions, acquisitions and other strategic deals. She also counseled boards and senior management on U.S. securities law and Nasdaq/NYSE compliance. Most recently, Rav was an associate at a Beverly Hills law firm, where she advised clients on mergers and acquisitions, corporate formations, governance matters and commercial real estate transactions.

Rav earned her Juris Doctor from the University of Southern California Gould School of Law, where she received the C. David Molina First Generation Professional Student of the Year Award and the Student Body Association Equity Diversity and Inclusion Fellowship Award. She graduated cum laude from the University of California, Los Angeles with a Bachelor of Arts in Political Science and Human Biology and Society. Rav has been recognized in Best Lawyers: Ones to Watch® in America  and is admitted to practice in California.

Results

Rav’s notable matters include her representation of:

  • The buyer in the $525 million carve-out of Real Alloy, Inc., the aluminum recycling division of Aleris, Inc.*
  • EQRx, Inc., a biopharmaceutical company, in its all-stock acquisition by Revolution Medicines, Inc. (Nasdaq: RVMD).*
  • A biotech company in its $150 million Series B financing round.*
  • A real estate developer in its acquisition of storage facilities in multiple states.*
  • A biotech company in its underwritten public offering of approximately $140.6 million.*
  • A pharmaceutical company in an “at-the-market” (ATM) offering for the sale of up to $145 in shares.*

*Denotes prior firm experience

Awards and Recognition

Awards and Recognition

Best Lawyers: Ones to Watch® in America, 2026

Industries

Education

University of Southern California, Gould School of Law, J.D., 2022

University of California, Los Angeles, B.A., cum laude, 2018

Admissions

  • California
Jump to Page

Glaser Weil Cookie Preference Center Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek
panfry31